Compare General Mills, Inc. (GIS) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs GSK plc — how do they compare? General Mills, Inc. trades at $38.66 (market cap $19.46B), while GSK plc trades at $52.85 (market cap $101.34B). The key difference: GSK plc is far larger — about 5.2× General Mills, Inc.'s market cap, and General Mills, Inc. pays the higher dividend (6.69%). Which is the better fit depends on your goals.
| GIS | GSK | |
|---|---|---|
Market Cap | $19.46B | $101.34B |
Sector | Consumer Staples | Health |
52-Week High | $51.27 | $61.18 |
52-Week Low | $32.17 | $36.20 |
Enterprise Value | $32.95B | $121.95B |
Dividend Yield | 6.69% | 3.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $38.95, up 6.83% in the last session, with a bullish technical signal from moving averages. The stock shows mixed earnings performance, beating estimates in Q3 2025 and Q2 2026 but missing in Q4 2025. Revenue declined to $19.49B in 2025, with net income margin turning negative at -0.48% for 2026. Recent news highlights partnerships in regenerative agriculture and cost-saving initiatives targeting $3 billion by 2030 to support margins amid soft demand.
The outlook is cautious; while valuation appears attractive with a P/E of 9.23, weak sales and profit pressure pose risks. Analyst consensus is mixed with 22.22% buy ratings, but the average price target of $36.14 suggests limited upside. Key risks include competitive pressures and macroeconomic headwinds affecting consumer spending.
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
